Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
Overview
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin is indicated in combination with cytarabine for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Chronic Phase Chronic Myeloid Leukemia
- Ewing's Sarcoma
- Lymphoma, Diffuse
- Myeloblastic Leukemia
- Non-Hodgkin's Lymphoma (NHL)
- Treatment-Related Acute Myeloid Leukemia
- Wilms' tumor
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.